Edwards Lifesciences (EW) executive has shares withheld for tax on vesting

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Daniel J. Lippis reported a small, routine share disposition tied to tax withholding. On the vesting of equity awards, the issuer withheld 377 shares of common stock at $95.18 per share to cover tax obligations under Rule 16b-3(e).

After this tax-withholding event, Lippis directly holds about 40,033.9103 shares of Edwards Lifesciences common stock. The transaction reflects compensation-related tax settlement rather than an open-market sale or a change in his investment stance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lippis Daniel J.

Role CVP, TAVR

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	377	$95.18	$36K

Holdings After Transaction: Common Stock — 40,033.91 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 377 shares Per-share valuation for withholding: $95.18 per share Shares held after transaction: 40,033.9103 shares +1 more

4 metrics

Shares withheld for taxes 377 shares Tax withholding on vesting, Form 4

Per-share valuation for withholding $95.18 per share Value used for 377 withheld shares

Shares held after transaction 40,033.9103 shares Direct ownership after tax withholding

Transaction code F Payment of tax liability by delivering securities

Key Terms

Rule 16b-3(e), tax withholding obligations, vesting of securities, tax-withholding disposition

4 terms

Rule 16b-3(e) regulatory

"to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e)"

tax withholding obligations financial

"Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities"

vesting of securities financial

"obligations incident to the vesting of securities in accordance with Rule 16b-3(e)"

tax-withholding disposition financial

"transaction_action: tax-withholding disposition"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/07/2026 - 06:56 PM Accepted by SEC EDGAR 07/07/2026 - 06:56 PM Learn about SEC filing dates

FAQ

What insider transaction did Edwards Lifesciences (EW) report for Daniel J. Lippis?

Edwards Lifesciences reported that executive Daniel J. Lippis had 377 common shares withheld to cover tax obligations on vesting equity. This was a compensation-related tax-withholding event, not an open-market purchase or sale of Edwards Lifesciences stock.

How many Edwards Lifesciences (EW) shares were involved in Daniel J. Lippis’s Form 4 filing?

The Form 4 shows 377 Edwards Lifesciences common shares were withheld. These shares were retained by the issuer to satisfy tax withholding obligations triggered by the vesting of equity-based compensation granted to Daniel J. Lippis.

At what price were the Edwards Lifesciences (EW) shares valued for Daniel J. Lippis’s tax withholding?

The withheld 377 Edwards Lifesciences shares were valued at $95.18 per share. This valuation is used solely for calculating the tax withholding amount tied to the vesting of Lippis’s equity awards, not as an open-market trade price.

How many Edwards Lifesciences (EW) shares does Daniel J. Lippis hold after this transaction?

Following the tax-withholding disposition, Daniel J. Lippis directly holds approximately 40,033.9103 shares of Edwards Lifesciences common stock. This remaining position reflects his direct ownership after accounting for the 377 shares withheld for tax purposes.

Was Daniel J. Lippis’s Edwards Lifesciences (EW) transaction an open-market sale?

No. The filing states the 377 shares were withheld by Edwards Lifesciences to satisfy tax withholding obligations on vesting awards. This is categorized as a tax-withholding disposition, not an open-market sale initiated by Daniel J. Lippis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TAVR

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/07/2026		F(1)		377	D	$95.18	40,033.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy tax withholding obligations incident to the vesting of securities in accordance with Rule 16b-3(e).

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)